An open-label evaluation of the utility of the Risperdal Consta treatment guidebook during transition of adult patients with schizophrenia or schizoaffective disorder to Risperdal Consta (risperidone) treatment over three months in the community mental health center (CMHC) setting

Trial Profile

An open-label evaluation of the utility of the Risperdal Consta treatment guidebook during transition of adult patients with schizophrenia or schizoaffective disorder to Risperdal Consta (risperidone) treatment over three months in the community mental health center (CMHC) setting

Completed
Phase of Trial: Phase III

Latest Information Update: 14 May 2007

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top